The federal government’s recent threat to penalize Johnson & Johnson (J&J) for its unapproved 340B rebate model could spark a [...] …
Month: September 2024
A federal district judge ruled that four drugmakers’ 340B contract pharmacy restrictions—as implemented in 2021—do not violate the 340B statute, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
You cannot predict when an audit will happen. But you can prepare.
If you operate a 340B covered entity (CE), you know HRSA will eventually come to review your 340B program compliance and integrity. But when?
HRSA’s
…
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Q: Tell us some interesting details about your company’s history.
Equiscript, founded in 2009 in Charleston, SC, provides tools and services that improve patient access to medications and health outcomes.
…
The federal agency that oversees the 340B program today formally warned Johnson & Johnson (J&J) that it must “cease implementation [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The sponsor of new Senate legislation that would codify providers’ ability to use contract pharmacies to dispense 340B discounted drugs [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
Being part of the 340B program is not just about saving money; it also requires careful management of those savings. To get the most out of the 340B program, organizations should accurately calculate savings and carefully manage and document how they are used.
…
A Washington, D.C.-based children’s hospital has sued the federal government for authorizing drugmaker Johnson & Johnson (J&J) to perform “unlawful” [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Four diabetes drugmakers are urging a federal appeals court to uphold a lower court’s decision to dismiss 340B antitrust claims [...] …
